Jefferies Initiates Coverage On Ascendis Pharma With Buy Rating, Announces Price Target of $150
Jefferies Initiates Coverage On Ascendis Pharma With Buy Rating, Announces Price Target of $150
傑富瑞集團以買入評級啓動對Ascendis Pharma的報道,宣佈目標股價爲150美元
Jefferies analyst Kelly Shi initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $150.
傑富瑞分析師凱利·施以買入評級開始報道Ascendis Pharma(納斯達克股票代碼:ASND),並宣佈目標股價爲150美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。